Oberhausen, Germany Clinical Trials

A listing of Oberhausen, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 445 clinical trials
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients 16 Years With Centronuclear Myopathies

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of a new medicine called DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1. The trial will …

universit tsklinikum Essen, Kinderklinik I, Sozialp diatrisches Zentrum
 (6.9 away) Contact site
  • 2 views
  • 19 Feb, 2021
  • +9 other locations
OL Extension Study of LNP023 in C3G

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy

Novartis Investigative Site
 (6.7 away) Contact site
  • 0 views
  • 01 Apr, 2021
  • +8 other locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab …

epidermal growth factor
afatinib
lung carcinoma
platinum-based chemotherapy
growth factor
Universitaetsklinikum Essen
 (6.7 away) Contact site
  • 5 views
  • 13 Jun, 2021
  • +86 other locations
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Momenta Investigational Site
 (6.7 away) Contact site
  • 15 views
  • 13 Jun, 2021
  • +131 other locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and …

trastuzumab
estrogen
cyclophosphamide
progesterone receptor
sentinel lymph node biopsy
Department of Gynecology and Obstetrics, Marienhospital
 (3.3 away) Contact site
  • 17 views
  • 24 Jan, 2021
  • +50 other locations
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk HR+/HER2- EBC

The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of-care chemotherapy (followed by adjuvant endocrine therapy).

breast cancer
endocrine therapy
direct bilirubin
HER2
hormone therapy
Kliniken Essen-Mitte, Klinik f r Senologie/Interdisziplin res Brustzentrum
 (8.5 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +7 other locations
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

somatomedin c
octreotide
igf1
insulin-like growth factor
hepatic disease
Universit tsklinikum Essen
 (6.9 away) Contact site
  • 15 views
  • 30 May, 2021
  • +48 other locations
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial.

somatomedin c
hepatic disease
octreotide
igf1
insulin-like growth factor
Universit tsklinikum Essen
 (6.9 away) Contact site
  • 60 views
  • 04 Jun, 2021
  • +48 other locations
Efficacy Safety and Tolerability of Atogepant for the Prevention of Chronic Migraine

This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.

headache
migraine
Universit tsklinikum Essen (A R), Klinik f r Neurologie
 (6.7 away) Contact site
  • 576 views
  • 02 Jun, 2021
  • +178 other locations
A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Universit tsklinikum Essen
 (6.7 away) Contact site
  • 113 views
  • 12 Jun, 2021
  • +124 other locations